Canadian biotechnology company Zymeworks Inc. has announced the acquisition of Theravance Biopharma in a deal valued at approximately $929 million. While the acquisition may appear to be just another merger in the pharmaceutical industry, it represents a major strategic transformation for Zymeworks.
Until now, Zymeworks has primarily focused on developing innovative cancer therapies. By acquiring Theravance Biopharma, the company will gain access to an approved commercial respiratory medicine, recurring royalty income, and stronger cash flow, reducing its dependence on experimental oncology drugs.
Zymeworks to Acquire Theravance Biopharma Latest News
On June 29, 2026, Zymeworks announced that it had entered into a definitive agreement to acquire Theravance Biopharma for $17 per share in cash. In addition, Theravance shareholders will receive a Contingent Value Right (CVR), allowing them to benefit from potential future value generated by the company’s experimental drug, ampreloxetine.
The transaction has been unanimously approved by the boards of both companies and is expected to close in the second half of 2026, subject to shareholder approval and customary regulatory clearances.
Key Highlights of the Acquisition
| Particular | Details |
| Acquirer | Zymeworks Inc. |
| Target Company | Theravance Biopharma Inc. |
| Deal Value | Approximately US$929 Million |
| Offer Price | US$17 per share (Cash) |
| Payment Structure | Cash + Contingent Value Right (CVR) |
| Expected Closing | Second Half of 2026 (Subject to regulatory and shareholder approvals) |
| Acquirer Exchange | Nasdaq |
| Acquirer Ticker | ZYME |
| Target Exchange | Nasdaq |
| Target Ticker | TBPH |
| Acquirer Country | Canada |
| Target Country | Cayman Islands (Operational headquarters in the United States and Ireland) |
| Industry | Biotechnology / Biopharmaceuticals |
| Primary Therapeutic Areas | Oncology (Zymeworks) + Respiratory & Specialty Medicines (Theravance) |
| Key Commercial Asset Acquired | YUPELRI (revefenacin) – FDA-approved COPD treatment |
| Strategic Benefits | Commercial revenue, royalty income, business diversification, stronger cash flow, and valuable tax assets |
| Funding Sources | OMERS Life Sciences financing, Zymeworks cash reserves, Theravance cash balance, and potential TRELEGY milestone payment |
About Zymeworks
Zymeworks Inc. is a Canada-based clinical-stage biotechnology company specializing in the discovery and development of next-generation biologic medicines.
Core Business
- Developing innovative cancer therapies
- Designing bispecific and multispecific antibodies
- Advancing oncology-focused clinical programs
- Partnering with global pharmaceutical companies through licensing agreements
The company uses advanced protein engineering technologies to develop targeted therapies aimed at improving cancer treatment outcomes.
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines for respiratory diseases and other specialty conditions.
Its major assets include:
- YUPELRI (revefenacin) – an FDA-approved treatment for COPD
- Royalty interests related to TRELEGY
- Experimental drug Ampreloxetine
- Significant cash reserves
- Valuable Ireland-based tax assets
Although the company faced setbacks in some late-stage clinical trials, it continues to own commercially valuable products and royalty-generating assets.
What is a Contingent Value Right (CVR)?
One of the most interesting aspects of this transaction is the CVR.
A Contingent Value Right gives Theravance shareholders the opportunity to receive additional payments if the company’s experimental drug Ampreloxetine is successfully licensed, commercialized, or generates future value.
This structure allows shareholders to receive immediate cash while also participating in any future upside.
Why is Zymeworks Acquiring Theravance Biopharma?
1. Immediate Commercial Revenue
Unlike Zymeworks’ experimental pipeline, YUPELRI is already an approved and marketed product.
This means the company will begin generating commercial revenue immediately after the acquisition closes.
2. Business Diversification
Zymeworks has traditionally relied on oncology research.
Adding respiratory medicines and royalty-generating assets reduces the company’s dependence on a single therapeutic area and creates a more diversified business model.
3. Stronger Cash Flow
Commercial products generate recurring revenue that can support future research and development.
This provides greater financial stability while funding the company’s long-term innovation strategy.
4. Valuable Royalty Portfolio
Theravance owns royalty interests in several pharmaceutical products.
These royalties are expected to provide Zymeworks with an additional source of recurring income.
5. Tax Advantages
Theravance also brings valuable Irish tax assets that could improve the combined company’s tax efficiency and long-term profitability.
Why is YUPELRI Important?
YUPELRI (revefenacin) is an FDA-approved once-daily nebulized therapy used to treat Chronic Obstructive Pulmonary Disease (COPD).
COPD is a serious chronic lung disease affecting millions of patients worldwide.
Since YUPELRI is already available in the market, it provides Zymeworks with an established commercial product and a steady source of revenue from day one.
How Will the Acquisition Be Financed?
Zymeworks has structured the transaction using multiple funding sources.
The financing includes:
- Approximately $350 million in non-recourse financing from OMERS Life Sciences
- Around $219 million from Zymeworks’ existing cash reserves
- Approximately $360 million of Theravance’s expected cash at closing
- A potential future $100 million milestone payment related to TRELEGY, which could further reduce the effective acquisition cost
Why Did Theravance Agree to Sell?
Earlier in 2026, Theravance experienced disappointing Phase 3 clinical trial results for its experimental drug Ampreloxetine.
Following the setback, the company initiated a strategic review to evaluate its future options.
After reviewing multiple alternatives, the board concluded that Zymeworks’ offer delivered the best value for shareholders by providing immediate cash consideration along with future upside through the CVR.
What Does This Mean for Investors?
For Zymeworks Investors
Potential Benefits
- Immediate commercial revenue
- Diversified business model
- Stable royalty income
- Stronger operating cash flow
- Reduced dependence on oncology pipeline
- Improved long-term growth opportunities
Potential Risks
- Integration challenges
- Competitive respiratory market
- Financing and execution risks
- Dependence on successful commercialization of acquired assets
For Theravance Investors
- Immediate cash payment
- Opportunity for additional future value through the CVR
- Reduced clinical development risk
- Clear shareholder exit at a premium valuation
Industry Impact
This acquisition reflects a broader trend in the biotechnology industry.
Instead of relying solely on experimental drug pipelines, many biotech companies are now combining commercial products, recurring royalty income, and innovative research pipelines to create more sustainable and financially resilient businesses.
The Zymeworks–Theravance transaction is a strong example of this evolving strategy.
Outcome
Zymeworks’ $929 million acquisition of Theravance Biopharma is one of the most significant biotechnology deals of 2026. The transaction transforms Zymeworks from a primarily oncology-focused biotech company into a more diversified pharmaceutical business with commercial revenue, royalty-generating assets, stronger cash flow, and valuable tax benefits.
For Theravance shareholders, the deal offers immediate cash value along with the possibility of future returns through the Contingent Value Right. If regulatory approvals are received as expected, the acquisition is anticipated to close in the second half of 2026, marking a new growth chapter for both companies.
Source: Zymworks news
